{
  "ticker": "SPL",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975086",
  "id": "02975086",
  "pages": 8,
  "price_sensitive": true,
  "date": "20250731",
  "time": "0949",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mccmcmjx4sy9.pdf",
  "summary": "### **Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Operational/Financial Highlights**:  \n- **Cash balance (30 Jun 2025)**: **$15.4M** (~7.7 quarters of funding).  \n- **Customer receipts (Q4)**: **$2.0M** (+51% QoQ), driven by Viraleze\u2122 and VivaGel\u00ae BV sales.  \n- **FY25 underlying receipts**: **$4.9M** (+165% YoY, excluding one-time FY24 Mundipharma exit).  \n- **R&D Tax Incentive**: Expected **$3.5M** inflow in H1 FY26.  \n- **Business development**: Signed VivaGel\u00ae BV distribution agreement (Synmosa, covering Philippines/Malaysia/Singapore); Viraleze\u2122 pre-launch in Saudi Arabia.  \n- **R&D progress**: DEP\u00ae radiotheranostics preclinical work ongoing; 2 new Star Navigator collaborations initiated.  \n\n#### **Cash Flow Summary (Q4)**:  \n- **Net operating cash outflow**: **($2.0M)** (R&D: $1.8M, staffing: $2.0M).  \n- **Debt facility**: **$0.38M total** ($0.17M drawn).  \n\n*No material capital-raising or trading halt information identified.*",
  "usage": {
    "prompt_tokens": 6263,
    "completion_tokens": 289,
    "total_tokens": 6552,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-31T00:07:31.505398"
}